News - Ceftobiprole Approved in Canada for Treatment of Complicated Skin Infections

	Unregistered User Click here if this is not your Personal Edition
		Contact Us \| Free E-Mail Updates \| Journals \| Register a colleague

Bacterial Infections

EXPLORE :

Most Read News

All News

All Webcasts / CME

All Cases

Congress Resource Centre

All Medical Resources

My Personal Edition

Warning | Privacy

Recent news - Bacterial Infections

	TopAbstracts in Bacterial Infections 10/13/2008 - (DGNews)
	Procalcitonin Can Help Identify Infants at High Risk for Serious Bacterial Infections - (DGNews)
	Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial - (JAMA)
	Changing Dosing, Administration of Anthrax Vaccine Reduces Side Effects - (DGNews)
	TopAbstracts in Bacterial Infections 09/29/2008 - (DGNews)

News archive

Recent webcasts/CME - Bacterial Infections

Reducing the Burden of Overactive Bladder: A Global Perspective

	C. difficile - A Community Epidemic
	Pulmonary Complications of Anti-Tumor Necrosis Factor-a Therapy
	Silica-Related Lung Disease: It's Still Here
	Botulism: Diagnosis and Management

Webcasts/CME archive

Recent cases - Bacterial Infections

	Ventriculitis Due to Staphylococcus Lugdunensis: Two Case Reports
	Six Mantoux Tuberculin Skin Tests with 1, 2, 5, 10, 20, And 50 Units in a Healthy Male Without Side-Effects - Is Skin Reaction a Linear Function of Tuberculin Dose?: A Case Report
	An Elderly Woman with 'Red Man Syndrome' in Association with Oral Vancomycin Therapy: A Case Report
	Neonatal Group A Streptococcal Meningitis: A Case Report and Review of the Literature
	Bacillus Cereus Endocarditis in a Permanent Pacemaker: A Case Report

Cases archive

my personal edition > bacterial infections > news

E-Mail this DGNews to a colleague

DGNews

Ceftobiprole Approved in Canada for Treatment of Complicated Skin Infections

BASEL, Switzerland -- June 30, 2008 -- Health Canada has authorised the marketing of ceftobiprole medocaril for injection (ZEFTERA) for the treatment of complicated skin and soft tissue infections including diabetic foot infections.

Ceftobiprole is the first approved broad-spectrum anti-methicillin-resistant Staphylococcus aureus (MRSA) antibiotic belonging to the cephalosporin class. It is specially designed to bind the penicillin-resistant targets in many Gram-positive bacteria of the cocci-type, resulting in bactericidal activity towards MRSA and penicillin-resistant Streptococcus pneumoniae.

Ceftobiprole as a single intravenous agent has demonstrated broad-spectrum activity against many other Gram-positive as well as Gram-negative bacteria, frequently associated with community and hospital-acquired infections.

SOURCE: Basilea Pharmaceutica Ltd.

E-Mail this DGNews to a colleague

To print, use this version